Yahoo Finance Exopharm Full Year 2023 Earnings: AU$0.036 loss per share (vs AU$0.064 loss in FY 2022)
Exopharm (ASX:EX1) Full Year 2023 Results
Key Financial Results
Revenue: AU$3.41m (down 19% from FY 2022).
Net loss: AU$7.13m (loss narrowed by 29% from FY 2022).
AU$0.036 loss per share (improved from AU$0.064 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Exopharm shares are down 11% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 6 warning signs for Exopharm you should be aware of, and 5 of them are potentially serious.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
